Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.

Tian ShenShanhua ZhengLei GengZhengtao LiuJun XuBingyi LinJunjie QianShushen Zhen

Published in: Technology in cancer research & treatment (2021)

Anti-PD-1 antibody camrelizumab had a manageable safety profile in patients with advanced BTC. This initial assessment of camrelizumab monotherapy provides effective evidence for patients with refractory BTC in biomarker-unselected patients.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
combination therapy
open label
peritoneal dialysis
case report
clinical trial
study protocol